about
Guillain–Barré Syndrome—A Classical Autoimmune Disease Triggered by Infection or VaccinationNeuropsychiatric lupus: a mosaic of clinical presentationsComparable long-term efficacy of Lopinavir/Ritonavir and similar drug-resistance profiles in different HIV-1 subtypesThe new H1N1 and HPV vaccines and old fears.The thrombophilic network of autoantibodies in celiac disease.The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence.Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients.Thymoma and autoimmunity.Vitamin D and autoimmune thyroid diseasesEULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants.Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature.Sjögren's syndrome, the old and the new.Fibromyalgia and cytokines.16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus.Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?Transverse myelitis and vaccines: a multi-analysis.Prevalence of celiac disease in latin america: a systematic review and meta-regression.Individual olfactory perception reveals meaningful nonolfactory genetic informationCarcinoma of colon presenting as fever of unknown origin.Prediction and prevention of autoimmune skin disorders.Infection and primary biliary cirrhosis.Mycobacterium tuberculosis, autoimmunity, and vitamin D.Infections and autoimmunity--friends or foes?Vaccines and autoimmunity.Molecular mimicry in systemic lupus erythematosus.Adjuvants and autoimmunity.Parkinson's disease, autoimmunity, and olfaction.Defining and analyzing geoepidemiology and human autoimmunity.Vaccines and autoimmune diseases of the adult.Geoepidemiology of autoimmune rheumatic diseases.Silicone and autoimmunity.Macrophagic myofaciitis a vaccine (alum) autoimmune-related disease.EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases.Infectious agents in the pathogenesis of primary biliary cirrhosis.Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature.Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia.Delayed allergic reaction after coronary angiography.Superior vena cava syndrome - changing etiology in the third millennium.Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment.
P50
Q24276196-9F233B4B-2804-47DD-BEFB-C48077341524Q27027588-5E8BB6E2-F594-4E1B-83A8-7B78671E047FQ28539169-04F808F0-A558-4DBC-B85C-98702CF33A82Q30389423-73471F7A-3696-4BDD-B06D-20F938704DACQ33355589-760B33FA-A11A-4327-B260-E78E7D483118Q33382314-580BD80C-D2F0-464F-82B8-2F40BC477B9BQ33394453-C026B318-EDF4-4C65-8B2E-D539FB91C37DQ33577486-D9114297-B7FB-4ACD-B90B-0D83AE5C54A5Q33577498-9A448F59-36F4-428E-8C75-93CC35428727Q33731711-9C86FDDF-0EE9-482B-8AED-F1EEECE53741Q34023471-1F384DE6-7436-46B5-8B2E-D214E694B033Q34164524-DB5EE043-1475-4BC2-BCEE-D68D845D60A2Q34261915-E1BF6254-FF36-43C8-9F3F-59FD54396FD8Q34400019-280E589B-2AC4-492C-81B0-B4D2A39615DCQ34654431-EE64C09B-39D4-44A0-A7D9-0837D54355EFQ34660000-2DC16A54-567F-4EBC-87C8-C6D07E261906Q35010738-B7C698ED-FA3E-4666-A29C-3ACC8FA574F1Q35571575-21DAE8B9-D56E-4033-A5BD-B3095293C0F7Q35865564-417C80F6-393F-4626-A5DF-33A2E3852BB0Q36164654-AE9953B1-017D-4695-899B-25429CA8D58CQ37278935-F9E6C536-73E2-46CE-ADFC-9A05B7E18BD8Q37477095-80EEBA55-41BD-4CB8-985D-CF9E7BFF7B7FQ37526582-17DD39A7-A777-4A03-A2C9-980E7C39F8D0Q37567077-6A6A6F56-45D5-4D8E-BA04-66FE90A4C76EQ37623438-5BC26865-5392-41A5-AF72-FD10457C257EQ37625583-09E6FDCA-1DEC-4800-ACB3-2241CA9F9DDFQ37625591-EB571F18-D32C-41F1-999F-B3B1448CE9FDQ37633575-E81C498F-EAB4-43DA-A488-D4F9EB6776A0Q37662596-EBFD408C-ACB1-4054-81B7-BC7CD5A7D4D7Q37700919-96B6761E-AA3B-4CC8-8083-C51C819664E5Q37700919-B6943AB0-415B-4D58-9608-2A68FDBAFCF7Q37766752-BB91CDF7-C46B-4C0F-A626-036797CEEEBDQ37794207-C94F8F9F-AF20-4230-AAD8-8B8517A680FAQ37794845-32529E38-1816-4F8F-B220-6CA88454F9E0Q37816066-840C29AB-8123-4964-AA05-F48B5B9213AEQ37836235-45200D93-BD41-4B8E-B058-F06394209631Q37869991-F96765CB-C63D-4573-98FF-C4BDC93CD164Q37883979-DDF08525-2443-4476-8E73-F811C4F024F4Q37885125-8E432728-4B27-477C-B8D4-1CAA0949C0FEQ37918047-68335C84-43F8-4119-BF4C-BEA1E70B64C5
P50
description
forsker
@nb
onderzoekster uit Israël
@nl
researcher
@en
name
Nancy Agmon-Levin
@da
Nancy Agmon-Levin
@de
Nancy Agmon-Levin
@en
Nancy Agmon-Levin
@es
Nancy Agmon-Levin
@fr
Nancy Agmon-Levin
@nb
Nancy Agmon-Levin
@nl
Nancy Agmon-Levin
@nn
Nancy Agmon-Levin
@sv
type
label
Nancy Agmon-Levin
@da
Nancy Agmon-Levin
@de
Nancy Agmon-Levin
@en
Nancy Agmon-Levin
@es
Nancy Agmon-Levin
@fr
Nancy Agmon-Levin
@nb
Nancy Agmon-Levin
@nl
Nancy Agmon-Levin
@nn
Nancy Agmon-Levin
@sv
prefLabel
Nancy Agmon-Levin
@da
Nancy Agmon-Levin
@de
Nancy Agmon-Levin
@en
Nancy Agmon-Levin
@es
Nancy Agmon-Levin
@fr
Nancy Agmon-Levin
@nb
Nancy Agmon-Levin
@nl
Nancy Agmon-Levin
@nn
Nancy Agmon-Levin
@sv
P214
P106
P21
P214
P27
P31
P496
0000-0001-9514-3677
P7859
lccn-n2015181561